Mar 21, 2026 by Jeremy BowmanThe Iran War Just Triggered a Bigger Energy Shock Than the 1970s Oil Crisis. What It Means for Your Portfolio.The war will likely continue to roil markets.
Mar 21, 2026 by Jeremy BowmanGoldman Sachs Just Sounded the Alarm on Private Credit. Here Are 2 Things Investors Need to Know.A crisis could be building in the private credit market.
Mar 21, 2026 by Adam Levy1 Cryptocurrency to Buy Before It Soars Over 1,300%, According to an Expert AnalystAfter a big downturn in the crypto market, are investors flush with opportunities?
Mar 21, 2026 by James HiresThe Tech Stock With More Potential Than Any CryptocurrencyBitcoin has potential, so do Ethereum, Monero, and all the others, but ASML has even more as the monopoly underpinning the whole tech industry.
Mar 21, 2026 by Adam LevyCould Buying $10,000 of Sandisk Make You a Millionaire?Sandisk has been the hottest stock in the market since its debut. Can it keep climbing?
Mar 21, 2026 by Catie HoganBetter Cybersecurity Stock: Okta vs. ZscalerBoth companies are leaders in their industry, but face a fast-changing landscape.
Mar 21, 2026 by Adé HennisMaze Therapeutics President Sells All Insider Shares as Q4 Earning Report NearsThis pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings report.
Mar 21, 2026 by Dave Kovaleski2 Financial Stocks That Could Double Over the Next 5 YearsWall Street is bullish on these two fintech stocks.
Mar 21, 2026 by Neil PatelIf You Invested $10,000 in Tesla Stock 10 Years Ago, Here's How Much You'd Have TodayTesla shareholders have earned every penny of the monster gains registered over the past decade.
Mar 21, 2026 by Adam Levy1 Cryptocurrency to Buy Before It Soars Over 1,300%, According to an Expert AnalystAfter a big downturn in the crypto market, are investors flush with opportunities?
Mar 21, 2026 by Maurie Backman3 Less-Obvious Benefits of Retiring LateIt could pay to extend your career.
Mar 21, 2026 by Jonathan PoncianoThis $9 Million Solar Bet Lands Amid an 82% Stock Surge and $3 Billion Revenue YearSunrun delivers residential solar and battery storage solutions to U.S. homeowners through a direct-to-consumer model.
Mar 21, 2026 by Adé HennisCentury Aluminum CEO Sells 150000 Shares as Aluminum Prices SoarThis aluminum producer has been flourishing, and with the metal's price soaring, the company continues to benefit.
Mar 21, 2026 by Lawrence NgaPrediction: 2 Things That Will Happen to Alibaba in 2026Alibaba's e-commerce empire may no longer be the company's biggest growth story. Instead, artificial intelligence and cloud infrastructure are quickly taking center stage.
Mar 21, 2026 by Jonathan PoncianoThis Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight ResetThis clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.
Mar 21, 2026 by Keithen DruryIs the Stock Market Sending a Warning Signal About Artificial Intelligence (AI) Stocks?AI stocks have had a bad 2026 so far.
Mar 21, 2026 by Adé HennisRalliant Director Purchases 2350 Shares as Institutional Investors Push for Stock BuybackAfter a rough Q4 FY 2025 earnings, Ralliant's stock has reached an all-time low. Yet, one of the company's board directors purchased insider shares after the underwhelming earnings.
Mar 21, 2026 by Jonathan PoncianoThis $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue GrowthThis healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
Mar 21, 2026 by Adé HennisVita Coco CFO Sells 4000 Shares as Stock Sets to Join S&P SmallCap 600This global beverage company had a strong run in 2025, and now, its stock is set to join one of the top funds in the market.
Mar 21, 2026 by Jonathan PoncianoThis $8.9 Million Buy Targets a Stock Down 68% With $322 Million in CashBiohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.
Mar 21, 2026 by Jonathan PoncianoThis New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround StoryThis biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
Mar 21, 2026 by Katie BrockmanWhat Happens to Your Investments If the Stock Market Crashes?There's good news and bad news for investors right now.
Mar 21, 2026 by Jonathan PoncianoThis $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug LaunchCogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
